Kazuhiro Kobayashi Selected Research

Walker-Warburg Syndrome

1/2018	Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
1/2016	Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
10/2015	Founder mutation causes classical Fukuyama congenital muscular dystrophy (FCMD) in Chinese patients.
2/2015	Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
8/2013	Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients.
4/2013	[Fukuyama muscular dystrophy: elucidation of the gene and pathogenesis and approaches toward molecular targeting therapy].
7/2012	Detection of the dystroglycanopathy protein, fukutin, using a new panel of site-specific monoclonal antibodies.
1/2012	[Molecular targeting therapy for Fukuyama muscular dystrophy].
10/2011	Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
12/2006	Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuhiro Kobayashi Research Topics

Disease

21	Muscular Dystrophies (Muscular Dystrophy) 01/2022 - 03/2002
14	Walker-Warburg Syndrome 01/2018 - 03/2002
6	Neoplasms (Cancer) 01/2021 - 01/2008
4	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2002
3	Heart Failure 11/2019 - 01/2006
3	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 05/2016
3	Carcinogenesis 08/2018 - 01/2013
2	Obesity 01/2022 - 01/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2021
2	Overactive Urinary Bladder (Overactive Bladder) 01/2022 - 01/2021
2	Atrophy 01/2021 - 08/2005
2	Hydrocephalus (Hydrocephaly) 01/2021 - 03/2003
2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 04/2013
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2018 - 11/2013
2	Hypertension (High Blood Pressure) 11/2018 - 05/2014
2	Atherosclerosis 01/2018 - 06/2017
2	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2017
2	Hypothermia 03/2016 - 10/2011
2	Ischemia 03/2016 - 10/2011
2	Alopecia (Baldness) 01/2016 - 12/2005
2	Viral Encephalitis 04/2015 - 04/2014
2	Infections 04/2015 - 01/2008
2	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 06/2013 - 11/2009
2	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 07/2012 - 02/2009
2	Peritonitis 01/2008 - 01/2006
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Cardiomyopathies (Cardiomyopathy) 01/2022
1	Body Weight (Weight, Body) 12/2021
1	Residual Neoplasm 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Testicular Microlithiasis 11/2020
1	Hypogonadism (Hypergonadotropic Hypogonadism) 09/2020
1	Dementia (Dementias) 01/2020
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2020
1	Asthenozoospermia 01/2020
1	Male Infertility (Male Sterility) 01/2020
1	Oligospermia (Oligozoospermia) 01/2020
1	Mental Disorders (Mental Disorder) 01/2020

Drug/Important Bio-Agent (IBA)

16	Dystroglycans (Dystroglycan)IBA 01/2022 - 03/2002
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2005
7	protein O-mannose beta-1,2-N-acetylglucosaminyltransferaseIBA 01/2016 - 03/2002
5	Pharmaceutical PreparationsIBA 01/2022 - 04/2013
5	RibitolIBA 01/2022 - 03/2016
4	Phosphates (Orthophosphate)IBA 01/2022 - 03/2016
4	Polysaccharides (Glycans)IBA 01/2020 - 01/2016
4	Triglycerides (Triacylglycerol)IBA 01/2018 - 01/2014
4	Galectin 3 (LGALS3)IBA 03/2016 - 10/2011
3	Laminin (Merosin)IBA 01/2018 - 06/2003
3	GlycosyltransferasesIBA 01/2016 - 12/2006
2	ZincIBA 12/2021 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 01/2018
2	Luteinizing Hormone (Lutropin)FDA LinkGeneric 11/2020 - 09/2020
2	Testosterone (Sustanon)FDA Link 09/2020 - 06/2017
2	TransferasesIBA 01/2020 - 01/2018
2	AndrogensIBA 01/2019 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 06/2017 - 01/2012
2	Indicators and Reagents (Reagents)IBA 03/2016 - 05/2014
2	Mannose (D-Mannose)IBA 01/2016 - 10/2010
2	Hematoxylin (Haematoxylon)IBA 01/2013 - 10/2011
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2013 - 10/2011
2	Retinaldehyde (Retinal)IBA 05/2012 - 08/2008
2	LigandsIBA 03/2012 - 10/2010
2	NucleotidesIBA 11/2009 - 08/2005
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Terpenes (Terpenoids)IBA 01/2022
1	ProdrugsIBA 01/2022
1	CholesterolIBA 01/2022
1	Zonisamide (Zonegran)FDA LinkGeneric 01/2022
1	cytidine diphosphate ribitolIBA 01/2022
1	EnzymesIBA 01/2022
1	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2022
1	Sterol Regulatory Element Binding Protein 2IBA 01/2022
1	CopperIBA 12/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Ifosfamide FDA LinkGeneric 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Follicle Stimulating Hormone (Follitropin)FDA Link 11/2020
1	Insulin (Novolin)FDA Link 09/2020
1	Dehydroepiandrosterone SulfateIBA 09/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	bu-zhong-yi-qi-tangIBA 01/2020
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2020
1	astaxanthine (astaxanthin)IBA 01/2020
1	Vitamin E FDA LinkGeneric 01/2020
1	Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 01/2020
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2020
1	AntioxidantsIBA 01/2020
1	coenzyme Q10 (CoQ10)IBA 01/2020

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2006
5	Drug Therapy (Chemotherapy) 01/2021 - 04/2013
4	Radiotherapy 01/2021 - 04/2013
4	Continuous Ambulatory Peritoneal Dialysis (CAPD) 01/2008 - 01/2006
3	Transplantation 01/2021 - 04/2005
3	Peritoneal Dialysis 12/2008 - 01/2006
2	Heart Transplantation (Grafting, Heart) 11/2019 - 01/2014
2	Catheters 01/2008 - 04/2007